drugset / Trial / NCT03587142
Buspirone for Early Satiety and Symptoms of Gastroparesis
Phase 2
Completed
96 enrolled
Johns Hopkins Bloomberg School of Public Health
Johns Hopkins University · collabMassachusetts General Hospital · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabTemple University · collabTexas Tech University Health Sciences Center, El Paso · collabUniversity of Louisville · collabWake Forest University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study evaluates whether the study medication, buspirone, an antianxiety drug, improves the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately severe symptoms of fullness and/or inability to eat a full meal. Half the patients will receive buspirone and half the patients will receive a placebo.
Timeline
- Start
- 2019-08-27
- Primary completion
- 2022-04-15
- Completion
- 2022-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Buspirone | Small molecule | 10 mg | Oral |